The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project has reported the important advances that have been made during the past year. Despite the negative impact of COVID-19, the Diagnostic and Patient Management Study (DPMS) succeeded in recruiting 844 of the planned 900 participants when recruitment was formally ended on 30 October 2020. A total of 245 people with Subjective Cognitive Decline, 342 with Mild Cognitive Impairment and 258 with dementia had been enrolled across eight European sites and will continue to be followed as scheduled. The data cleaning process has been initiated and the results on the primary endpoint are expected in mid-2021
In 2020, the Prognostic and Natural History Study (PNHS) saw great progress in the activation of all recruitment sites and the inclusion of additional Parent Cohorts. At this moment, the PNHS has 17 active sites and six cohorts have been actively enrolling into the study (EPAD LCS, EMIF-AD, ALFA+, FACEHBI, FPACK, UCL-2020-412), with two others confirmed to begin enrolment soon. In total, at the end of 2020, the AMYPAD PNHS had 754 participants consented of which 584 already underwent PET scanning. The data integration process (from all data sources) and quality check of data has been initiated.
In addition, the AMYPAD team has conducted a series of video interviews. Seven AMYPAD members explained the goal of each Work Package (WP) and the specific goals for 2021. Our project officer Cindy Birck was interviewed about the WP6 (Ethics, communication and dissemination) led by Alzheimer Europe. The video interviews can be found here. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.